GlassScriptPhysician profile
Trent A Hicks
NPI 1598420911
$3,830.72
in general payments reported to CMS, 2019-2025
35 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,219 · 2024: $1,110 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $609.49 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $404.20 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $314.73 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $255.54 | 2023-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $187.29 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.74 | 2025 | Caplyta |
| Astellas Pharma US INC | $119.61 | 2023-2025 | Veozah |
| Novo Nordisk INC | $114.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $96.59 | 2024-2025 | Auvelity, Symbravo |
| Lundbeck LLC | $90.86 | 2024-2025 | Rexulti |
| Corium, LLC | $74.58 | 2023-2025 | Azstarys |
| Pfizer INC. | $67.38 | 2023-2025 | |
| Lilly USA, LLC | $66.86 | 2023-2025 | Mounjaro, Jardiance |
| Dexcom, INC. | $61.89 | 2024-2025 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.10 | 2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $34.24 | 2023-2024 | Rytary, Unithroid |
| Vanda Pharmaceuticals INC. | $33.40 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $32.28 | 2024 | Gemtesa |
| Almatica Pharma LLC | $31.54 | 2024 | Loreev Xr |
| Sanofi Pasteur INC. | $28.35 | 2023 | |
| Exact Sciences Corporation | $27.89 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.67 | 2024 | Xifaxan |
| Ardelyx, INC. | $21.89 | 2025 | Ibsrela |
| Mylan Specialty L.P. | $21.47 | 2023 | Yupelri |
| Amgen INC. | $21.03 | 2023 | Otezla, Repatha |
| Boston Scientific Corporation | $20.75 | 2024 | Ams 700 |
| Acella Pharmaceuticals, LLC | $19.82 | 2024 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $18.54 | 2024 | Vaqta, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2023 | |
| Exeltis, USA INC. | $18.30 | 2024 | Slynd |
| Electromed, INC. | $18.14 | 2024 | Smartvest |
| Antares Pharma, INC. | $16.34 | 2024 | Xyosted |
| Shield Therapeutics INC | $14.75 | 2024 | |
| Verona Pharma, INC. | $13.59 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trent Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.